16307-08-7Relevant articles and documents
I2/TBHP mediated diastereoselective synthesis of spiroaziridines
Ashitha, Kizhakkan Thiruthi,Vinaya, Puthiya Purayil,Krishna, Ajay,Vincent, Deepthy Cheeran,Jalaja, Renjitha,Varughese, Sunil,Somappa, Sasidhar Balappa
supporting information, p. 1588 - 1593 (2020/03/06)
Eventhough spiroheterocycles are considered as emerging drug candidates, synthesis of spiroaziridines has not been well explored so far. Herein, we disclose an efficient I2/TBHP mediated diastereoselective synthesis of N-alkyl spiroaziridines from primary amines and easily accessible α,β-unsaturated ketones. The reaction is also compatible for the synthesis of 2-aroylaziridines.
Design and characterization of optimized adenosine A2A/A 1 receptor antagonists for the treatment of Parkinson's disease
Shook, Brian C.,Rassnick, Stefanie,Wallace, Nathaniel,Crooke, Jeffrey,Ault, Mark,Chakravarty, Devraj,Barbay, J. Kent,Wang, Aihua,Powell, Mark T.,Leonard, Kristi,Alford, Vernon,Scannevin, Robert H.,Carroll, Karen,Lampron, Lisa,Westover, Lori,Lim, Heng-Keang,Russell, Ronald,Branum, Shawn,Wells, Kenneth M.,Damon, Sandra,Youells, Scott,Li, Xun,Beauchamp, Derek A.,Rhodes, Kenneth,Jackson, Paul F.
experimental part, p. 1402 - 1417 (2012/04/04)
The design and characterization of two, dual adenosine A 2A/A1 receptor antagonists in several animal models of Parkinson's disease is described. Compound 1 was previously reported as a potential treatment for Parkinson's disease. Fu
ARYLINDENOPYRIMIDINES AND THEIR USE AS ADENOSINE A2a
-
Page/Page column 3; 4, (2009/05/29)
This invention relates to novel arylindenopyrimidines A, B, and C, and their therapeutic and prophylactic uses. Disorders treated and/or prevented using these compounds include Parkinson's Disease.
